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Glucans are (1®®®®® 3)-bbbbb -D-glucose polymers that are found
in the cell wall of fungi, bacteria and plants. G lucans
are known to stim ulate hum oral and cell-mediated im-
m unity in hum ans and anim als. In addition to the po-
tent im m une stim ulatory effects of (1®®®®® 3)-bbbbb -D-glucans,
there are a num ber of toxicological effects associated
with exposure to the water-insoluble, microparticulate
form  of the polym er. Recent investigations have suggest-
ed a potential role for (1®®®®® 3)-bbbbb -D-glucans in inhalation-
al  toxicity.  Specifically,  (1®®®®® 3)-bbbbb -D-glucans have  been
im plicated in the sym ptom atology associated with `sick
building’ syndrome. The m echanism s by which (1®®®®® 3)-
bbbbb -D-glucans m ediate im mune stim ulation and, perhaps,
toxicity are currently under investigation. It is now  es-
tablished  that  (1®®®®® 3)-bbbbb -D-glucans  are  recognized  by
m acrophages  and,  perhaps,  neutrophils  and  natural
killer cells via a (1®®®®® 3)-bbbbb -D-glucan specific receptor. Fol-
lowing receptor binding, glucan m odulates m acrophage
cytokine expression. Here we review the chem istry, im-
munobiology and toxicity of (1®®®®® 3)-bbbbb -D-glucans and how
it m ay relate to effects caused by inhalation.
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Introduction
Glucans are polym ers of glucose that are widely dis-
tributed  throughout  the  biosphere  [1].  Specifically,
glucans are found in the cell walls of plants, bacteria
and fungi, as minor constituents of fungal cytosol and
as polymers which are secreted into the environm ent
by  glucan-producing  m icroorganisms  [1].  Glucans
can be broadly classified according to the type of in-
trachain linkage of the polymer, as a - or b -linked [1].
The b -linked glucans are the predominant form found
in fungi [1]. It is the fungal-derived (1® 3)-b -D-glu-
cans which have been reported to modulate various
aspects  of  immunity  [2±5].  In the fungal cell  wall,
(1® 3)-b -D-glucans are linked to proteins, lipids and
other carbohydrates such as m annan [1].
The specific function of glucans in the physiology
of fungi is not clearly understood. However, it is gen-
erally considered that the prim ary function of these
polymers is a structural one in that they help to main-
tain the rigidity and integrity of the fungal cell wall
[1]. The glucan polymers in the fungal cell wall may
form a meshwork, due to the presence of (1® 6)-b -D-
glucopyranose side-chain branches, which may con-
nect adjacent (1® 3)-b -D-glucan polymers [1]. Fig. 1
shows the basic structure for a non-branched (1® 3)-
b -D-glucan polym er and for a (1® 3)-b -D-glucan pol-
ymer with single (1® 6)-b  side-chain branches.
Glucan  polym ers  can  exist  as  a  single  polym er
strand with a helical  conformation (single helix) or
as a stable complex of three polymer strands forming
a triple helix [6].  The triple helix, which appears to
be the preferred form, is stabilized by extensive hy-
drogen bonding at the O-2 hydroxyl [7±10].
Immunologic effects of (1® 3)-b -D-glucans
The ability of naturally occurring complex polysac-
charide polymers to modulate im munity has been well
documented  [2±5].  In  1959,  Benacerraf  et  al.  [11]
demonstrated that zymosan, a glucomannan isolated
from  Saccharomyces cerevisiae , produced marked hy-
perplasia and hyperfunctionality in fixed tissue m ac-
rophages. Di Luzio and Morrow [12], Cutler [13] and
Kelly  and  colleagues  [14]  confirmed  and  extended
the work of Benacerraf et al. [11]. In 1961, Riggi and
Di Luzio [15] demonstrated that glucan, a (1® 3)-b -
D-linked  glucopyranose  polym er,  was  the  m acro-
phage-stim ulating agent in zymosan. Numerous stud-
ies have shown that (1® 3)-b -D-glucan polymers will
increase the function of macrophages [16±19], neu-
trophils [20,21] and other immunocytes.  These ob-
servations have stimulated investigation into the po-
tential biomedical applications of polymeric (1® 3)-
b -D-glucans [4]. Unfortunately, there were also toxi-
cological effects associated with the systemic admin-248         Mediators of Inflammation ￿ Vol 6 ￿ 1997
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istration of these agents. Upon initial isolation from
yeast,  (1® 3)-b -D-glucans  are  usually  water-insolu-
ble microparticulates [6]. Systemic (intravenous) ad-
ministration of glucan microparticulates is associat-
ed with hypertrophy and hyperplasia of macrophage-
rich organs such as the liver, lung and spleen. Specif-
ically, granuloma form ation is observed [22]. Inter-
estingly, m any workers have reported that if (1® 3)-
b -D-glucans  are  converted  to  a  water-soluble  form ,
the immunologic activity is preserved, but the unde-
sirable side effects are elim inated [23].
The studies by Rylander and Fogelmark and col-
leagues [24±28] suggest that the effects of (1® 3)-b -
D-glucans in pulmonary symptomatology may include
synergy with endotoxin. Therefore, an im portant as-
pect of glucan’ s immunobiological activity is its ad-
juvant  effect.  Numerous  studies  have  demonstrated
the ability of (1® 3)-b -D-glucans to exert adjuvantic-
ity when combined with a variety of bacterial, viral
or parasite vaccines [29±36]. Glucan has been shown
to increase humoral and cell-mediated im m unity to
antigens [29±36]. In addition, glucans have demon-
strated  additive  or  synergistic  effects  on  immunity
when com bined with a variety of agents [17,19].
Receptor-mediated binding of a (1® 3)-b -D-glucan to
the human macrophage cell line U937
The  cellular  and  molecular  mechanism s  by  which
(1® 3)-b -D-glucans modulate im munity are just be-
ginning to emerge. We have shown that glucans me-
diate immunological activity, in part, via m acrophage
participation [17,19]. Fogelm ark  et al. [28] have spec-
ulated  that  glucans  mediate pulmonary  effects  due,
in part, to their effect on macrophages. The first step
FIG. 1. Primary structure of a single, non-branched and a single, branched (1 ® 3)-b -D-
glucan polymer. The backbone of the glucan polymer is composed of glucose subunits
connected by intrachain glycosidic (1® 3)-b -linkages. In a branched (1® 3)-b -D-glucan
polymer, the branches are connected by (1® 6)-b -linkages. In this model, the side-chain
branches are a single glucose subunit. Glucan polymers can exist as a single polymer
strand with a helical conformation (single helix) or as a stable complex of three polymer
strands forming a triple helix. The triple helical form is generally considered to be the
preferred form in nature.(1® 3)-b -D-glucan immunobiology
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in the interaction of glucan with m ammalian macro-
phages is thought to involve the binding of (1® 3)-b -
D-glucan to a macrophage receptor [37±40].  The  in
vivo significance of these receptor studies is uncer-
tain, because virtually all of these experim ents were
limited to in vitro phagocytosis and/or phagocytosis
inhibition assays [21,37,38]. More im portantly, vir-
tually all  of these studies used w ater-insoluble glu-
cans which were not chemically characterized [21,37,
38].
To  conclusively  dem onstrate  the  presence  of  a
(1® 3)-b -D-glucan-specific receptor requires a water-
soluble, chemically characterized, radiolabeled glu-
can  ligand.  We  have  developed  a  process  w hich
achieves  these  goals  [6].  Preliminary  data  with  the
human prom onocytic cell line U937 indicate that glu-
can phosphate binding obeys the criterion for specif-
ic binding  in  that  competition  for the binding  sites
can be dem onstrated in the presence of a 10-fold ex-
cess of unlabeled ligand [41].
Association binding studies were also undertaken.
In these experiments, U937 (1 ´ 10
6 cells) were co-
incubated with varying concentrations of 
3H-glucan
phosphate for 90 min (Fig. 2).
We observed a rate constant (K ob) of 0.95 min
±1, a
dissociation constant (K D) of 37 l mol/l and a maxi-
mum binding (B max) of 6.5 ´ 10
7 sites/cell. This indi-
cates a  medium-affinity  receptor and  rapid binding
of  the  ligand.  The  B max  value  m ore  than  accounted
for the entire U937 cell surface area. This suggested
that the glucan was being internalized following re-
ceptor binding.
Konopski et al. [42] have reported that murine mac-
rophages will bind and internalize a fluorescent la-
beled glucan, which is consistent with our observa-
tions. We have examined U937 cells by electron mi-
croscopy following glucan exposure and observed an
increase in phagolysosome formation which is con-
sistent with uptake of glucan [41]. We conclude that
the binding and internalization of glucans by human
macrophages is a two-phase process; the first phase
is a rapid binding of the glucan ligand to the receptor
and  is  followed  by  a  slower  uptake/internalization
phase. In subsequent studies, we examined the spe-
cificity  of  the  (1® 3)-b -D-glucan  receptor  on  U937
cells.  In  this  series  of  experim ents,  U937  (1 ´ 10
6
cells) was  incubated with 
3H-glucan phosphate and
varying  concentrations  of  unlabeled  glucan  phos-
phate, pullulan,  a (1® 4)-a -linked glucose polymer
and  schizophyllan,  a  branched  (1® 3)-b -D-glucan
polymer, for 90 min.
In this competitive binding study (Fig. 3), pullulan
did  not compete  for  binding to the (1® 3)-b -D-glu-
can  receptor.  Schizophyllan  showed  a  fivefold  in-
crease in affinity for the human macrophage (1® 3)-
b -D-glucan receptor compared to non-branched glu-
can phosphate. These data conclusively demonstrate
the presence of a (1® 3)-b -D-glucan-specific recep-
tor  on  a  hum an  macrophage-like  cell  line.  Further,
these  data  dem onstrate  that  the  glucan  receptor  is
specific  for  (1® 3)-b -linked  polym ers  and  that  the
glucan receptor has a higher affinity for one form of
glucan  over  another,  that  is,  branched  versus  non-
branched.
FIG. 3. Competitive displacement of tritiated glucan phosphate
and schizophyllan at 37°C. Pullulan (open squares) does not com-
pete for the same binding sites as unlabeled glucan phosphate
(GP, closed circles). Schizophyllan (SPG, open circles) does com-
pete for the same binding as unlabeled glucan phosphate and
has an approximate fivefold increase in affinity for the binding
site. The results are shown as means ± SEM of at least four rep-
licates from two separate experiments.
FIG. 2. Specific binding and internalization of glucan phosphate
to U937 cells. Combined saturation and competitive displacement
data yielded specific binding (sites per cell) to U937 as a function
of (1® 3)-b -D-glucan phosphate molarity at 37°C. We mathemati-
cally derived the dissociation constant (K D) and maximum bind-
ing (Bmax) value. The results are given as means and 95% confi-
dence intervals of means ± SEM from at least four replicates and
represent data from five separate experiments.250         Mediators of Inflammation ￿ Vol 6 ￿ 1997
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Conclusions
Indirect evidence continues to mount concerning the
potential involvement of (1® 3)-b -D-glucans  in  air-
ways  inflamm ation.  The  data  thus  far  suggest  that
glucans  m ust  act  in  concert  with  other  etiologic
agents, such as endotoxin, in order to mediate symp-
tomatology. Therefore, the prim ary role of (1® 3)-b -
D-glucans appears to be as an adjuvant which exerts
an additive or synergistic effect w hen combined with
other agents.
References
1. Ruiz-Herrera  J:  Biosynthesis  of  beta-glucans  in  fungi.  Antonie  Van
Leeuwenhoek 1991, 60:72±81.
2. Williams  D, Mueller A, Bro wder  W: Prevention and clinical evaluation of
carbohydrate immunopharmaceuticals in the pr evention of sepsis and se ptic
sequelae. J Endotoxin Res 1995, 2:203±208.
3. Williams DL, Pretus HA, McNamee RB, et al.: Development, physicochemi-
cal  characterization  and  preclinical efficacy  evaluation  of a  water  soluble
glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology
1991,  22 :139±156.
4. Browder W, Williams D , Pretus H, et al.: Beneficial effect of enhanced mac-
rophage function in the traum a patient. Ann Surg  1990, 211:605±613.
5. Williams D, Browder W: Development of na tural product (1® 3)-b -D-glucan
polymers as immune stimulating pharmaceuticals. Polymer Adv Tech 1994,
5:529±534.
6. Williams DL, McNamee RB, Jones EL, et al.: A method for the solubiliza-
tion of a (1® 3)-b -D-glucan isolated from Saccharomyces cerevisiae . Carbohy d
Res 1991, 219:203±213.
7. Ensley HE, Tobias B, Pretus HA, et al.: NMR spectral analysis of a water-
insoluble  (1® 3)-b - D-glucan  isolated  from   Saccharom yces  cerevisiae .
Carbohyd Res 1994, 258:307±311.
8. Marchessault RH, Deslandes Y: Fine structure of (1® 3)-D-glucans: curdlan
and  paramylon. Carbohyd Res 1994, 75:231±242.
9. Deslandes Y, Marchessault RH, Sarko A: Triple-helical structure of (1® 3)-
b -D-glucan. Macromolecules 1980, 13 :1466±1471.
10. Bluhm TL, Deslandes Y, Marchessault RH, Perez S, Rinaudo M: Solid-state
and solution conformation  of scleroglucan.  Carbohyd  Res 1982,  100:117±
130.
11. Benacerraf B,  Thorbecke  GJ, Jacob y  D:  Effect  of  zym osan on  endotoxin
toxicity in mice. Proc Soc Exp Biol M ed 1959, 100:796±799.
12. Di Luzio NR, Morrow SH: The fate of foreign red cells in mice with altered
reticuloendothelial  function.  Proc  Soc  Exp  Biol  M ed  1965,  119:647±
652.
13. Cutler JL: The enhancement of hemolysin production in the rat by zym osan.
J Immunol 1960, 84 :416±419.
14. Kelly  LS, Dobson EL, Finney CR,  Hirsch JD: Proliferation of  the reticu-
loendothelial system in the liver. Am J Physiol 1960, 198:1134±1138.
15. Riggi SJ, Di Luzio  NR: Identification  of a reticuloendothelial stimulating
agent in zym osan. Am J Physiol 1961, 200:297±300.
16. Sherwood ER, Williams DL, McNamee RB , Jones EL, Browder IW, Di Luzio
NR: In vitro tumoricidal activity of resting and glucan-activated Kupffer cells.
J Leukocyte Biol 1987, 42 :69±75.
17. Browder  W, W illiams  D,  Sherwood  E, McNamee  R, Jones  EL, Di  Luzio
NR: Synergistic effect of nonspecific immunostimulation and antibiotics in
experimental peritonitis. Surg ery 1987, 102:206±214.
18. Williams  DL,  DiLuzio NR:  Glucan-induced  modification  of  m urine viral
hepatitis. Science 1980, 208:67±69.
19. Williams DL, Sherwood ER, McNamee RB, Jones EL, Browder IW, Di Luzio
NR: Chemoimm unotherapy of experimental hepatic metastases. Hepatology
1987,  7:1296±1304.
20. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL: Effect
of glucan on neutrophil dynamics and imm une function in Escherichia coli
peritonitis. J Surg Res 1988, 44:54±61.
21. Williams JD, Topley N, Alobaidi HM, Harber MJ: Activation of human poly-
m orphonuclear leucocytes by particulate zymosan is related to both its ma-
jor  carbohydrate  com ponents:  glucan  and  mannan.  Imm unology  1986,
58:117±124.
22. Williams DL, Sherwood ER, McNamee RB, Jones EL, Di Luzio NR: Thera-
peutic efficacy  of glucan in a murine model of hepatic metastatic disease.
Hepatolog y 1985, 5:198±206.
23. Williams  DL, Sherwood  ER, Browder IW, McNamee RB,  Jones  EL: Pre-
clinical safety evaluation of soluble glucan.  Int J Immunopharmacol 1988,
10:405±411.
24. Goto H, Yuasa K, Rylander R: (1® 3)-b -D-glucan in indoor air, its measure-
ment and in vitro activity. Am J Ind M ed 1994, 25 :81±83.
25. Fog elmark B, Sjöstrand M, Rylander R: Pulmonary inflammation induced
by repeated inhalations of (1® 3)-b -D-glucan and endotoxin. Int J Exp Pathol
1994,  75 :85±90.
26. Rylander R, Fogelmark B: Inflammatory responses by inhalation of endo-
toxin and (1® 3)-b -D-glucan. Am J Ind Med 1994, 25:101±102.
27. Fog elmark B, Goto H, Yuasa K, Marchat B, Rylander R: Acute pulmonary
toxicity of inhaled b -1,3-glucan and endotoxin. Agents Actions 1992, 35 :50±
56.
28. Fog elmark B, Sjöstrand M, Rylander R: Pulmonary inflammation induced
by repeated inhalations of b (1,3)-D-glucan and endotoxin. Int J Exp Pathol
1994,  75 :85±90.
29. Holbrook TW, Cook JA, Parker BW: Glucan-enhanced imm unogenicity of
killed erythrocytic stages of Plasmodium berghei. Infect Immun  1981, 32:542±
546.
30. Holbrook  TW,  Cook  JA ,  Parker  BW:  Immunization  against  Leishmania
donovani: glucan as an adjuvant with killed prom astig otes.  Am J Trop M ed
Hyg 1981, 30 :762±768.
31. Cook  JA, Holbrook  TW:  Imm unogenicity  of  soluble  and  particulate anti-
gens from Leishmania donovani: effect of glucan as an adjuvant. Infect Immun
1983,  40 :1038±1043.
32. Holbrook TW, Cook JA : Non-specific and specific stimulation of resistance
against Leishmania donovani in C57Bl/6J Mice. Ann Clin Lab Sci 1983, 13:
411±417.
33. Holbrook TW, Cook JA : Immunization of mice against Leishmania donovani
by subcutaneous injections of dead promastigotes. Am J Trop Med Hyg 1983,
32:51±53.
34. Benach JL, Habicht GS, Holbrook TW, Cook JA: Glucan as an adjuvant for
a murine Babesia microti immunization trial.  Infect Immun 1982, 35:947±
951.
35. Lasarow RM, Williams DL, Theis JH: Humoral response following immu-
nization with Leishmania infantum (ex. Oklahoma): a com parison of adjuvant
efficacy in the antibody responses of Balb-C mice. Int J Imm unopharmacol
1992,  14 :767±772.
36. Williams  DL, Yaeger  RG,  Pretus  HA,  Browder IW,  McNamee  RB,  Jones
EL: Imm unization against Trypanosoma cruzi : adjuvant effect of glucan. Int
J Immunopharmacol 1989, 11 :403±410.
37. Abel G, Czop JK: Stimulation of human  monocyte  b -glucan  receptors by
glucan particles induces pr oduction of TNFa  and IL-b .  Immunopharmacol
1992,  14 :1363±1373.
38. Janusz MJ, Austen KF, Czop  JK:  Isolation  of a  unit  ligand  for  b -glucan
receptors  of  human  monocytes  [abstract].  Int J  Immunopharmacol  1988,
10:89.
39. Janusz  MJ, Austen  KF,  Czop  JK:  Isolation  of a  yeast  heptaglucoside  for
monocyte phagocytic b -glucan receptors [abstract]. FASEB J 1989, 3:6421.
40. Czop JK, Kay J: Isolation and characterization of b -glucan receptors on hu-
man mononuclear phagocytes.  J Exp Med 1991, 173:1511±1520.
41. Muller A, Rice PJ, Ensley HE, et al.: Receptor binding and internalization of
a water-soluble (1® 3)-b -D-glucan biologic response modifier in tw o mono-
cyte/macrophage cell lines. J Imm unol 1996, 156:3418±3425.
42. Konopski Z, Fandrem J, Selejid R, Eskeland T: Interferon inhibits endocy-
tosis of soluble animated  b -1,3-D-glucan and neutral red  in  mouse perito-
neal macrophages. J Interferon Cytokine Res 1995, 15 :597±603.